Keyphrases
19-gauge
16%
5-fluorouracil (5-FU)
17%
Acute Pancreatitis
20%
Adult-onset Type II Citrullinemia
16%
Advanced Gastric Cancer
84%
Amoxicillin
16%
Amrubicin
25%
Antithrombotic Drugs
16%
Atypical Manifestations
16%
Biopsy Needle
16%
Biopsy Specimen
23%
Blood Pressure
21%
Chemotherapy
32%
Chemotherapy-induced Diarrhea
25%
Cisplatin
60%
Clinical Trials
27%
Colonoscopic Polypectomy
16%
Colorectal Cancer
27%
Combination Chemotherapy
24%
Confidence Interval
17%
Constipation
16%
CTLN2
16%
Diarrhea
26%
Docetaxel
50%
Docetaxel Chemotherapy
16%
Drug Use
18%
Drug Users
16%
Endoscopic Hemostasis
33%
Endoscopic Papillectomy
16%
Endoscopic Retrograde Cholangiopancreatography
33%
Endoscopic Submucosal Dissection
42%
Endoscopic Ultrasound Guided Biopsy
16%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
53%
Endoscopy
22%
Extraintestinal Manifestations
16%
Fluoropyrimidine
35%
Franseen Needle
33%
Gancao
16%
Gastric Cancer
42%
Gastric Neuroendocrine Carcinoma
16%
Gastrointestinal Cancer
20%
Gastrointestinal Endoscopy
20%
Gastrointestinal Stromal Tumor
50%
Helicobacter Pylori (H. pylori)
35%
Heparin Bridging Therapy
16%
Hospital Meals
16%
IgA Vasculitis (IgAV)
16%
IgM Antibody
16%
Infectious Mononucleosis
16%
Inflammatory Bowel Disease
24%
Infliximab
33%
Interstitial Cells of Cajal
16%
Interstitial Lung Disease
16%
Intestinal mucosal Injury
18%
Intra-aortic Balloon Occlusion
33%
Irinotecan
32%
Japan
29%
Jejunum
33%
KIT Gene
21%
Lafutidine
16%
Lupus Erythematosus
16%
Median Overall Survival
28%
Median Progression-free Survival
33%
Monotherapy
25%
National Database
16%
Neuroendocrine Carcinoma
19%
Non-invasive Method
16%
Non-randomized Comparison
16%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
21%
Older Men
25%
Paclitaxel
22%
Pancreatitis
21%
Pathological Diagnosis
22%
PDGFRA mutation
16%
Phase II Study
19%
Protein-losing Enteropathy
16%
Proton Pump Inhibitors
30%
Pulmonary Involvement
16%
Randomized Controlled Trial
18%
Recurrent Lesions
16%
Resectable Pancreatic Cancer
16%
Risk Factors
27%
S-1 Plus Cisplatin
18%
Second-line Chemotherapy
17%
Shakuyakukanzoto
33%
Stag Beetle Knife
16%
Stenosis
21%
Stomach
33%
Submucosal Tumor
21%
Superficial Esophageal Neoplasm
16%
TJ-68
16%
Total Gastrectomy
16%
Treatment Outcome
18%
Triple Therapy
16%
Tumor
21%
Ulcer
33%
Ulcerative Colitis
33%
USE Questionnaire
16%
Warfarin
19%
Weekly Paclitaxel
16%
Medicine and Dentistry
Abdominal Cancer
55%
Adverse Event
14%
Antibody Response
16%
Antihypertensive
16%
Antithrombotic
18%
Arm
33%
Balloon Occlusion
33%
Biopsy Technique
29%
Bleeding
49%
Blood Pressure
21%
Cancer Recurrence
16%
Capsule Endoscopy
11%
Chemotherapy
27%
Cisplatin
10%
Citrullinemia Type II
16%
Clinical Trial
16%
Colon Ulcer
16%
Colorectal Carcinoma
14%
Computer Assisted Tomography
15%
Constipation
16%
Cytomegalovirus
16%
Diagnosis
36%
Diarrhea
14%
DNA Mismatch Repair
16%
Down Syndrome
16%
Drug Therapy
10%
Drug Use
18%
Duodenal Ulcer Bleeding
16%
Duodenum
22%
Duodenum Motility
16%
Duodenum Stenosis
16%
Endoscopic Hemostasis
33%
Endoscopic Papillotomy
16%
Endoscopic Retrograde Cholangiopancreatography
33%
Endoscopic Submucosal Dissection
42%
Endoscopic Ultrasound
33%
Endoscopic Ultrasound Guided Fine Needle Biopsy
47%
Endoscopy
39%
Epstein Barr Virus
10%
Esophagus Tumor
16%
Fine-Needle Aspiration
33%
Fluoropyrimidine
19%
Gastrointestinal Disease
16%
Gastrointestinal Endoscopy
19%
Gastrointestinal Stromal Tumor
33%
Gastrointestinal Tumor
16%
Glycyrrhiza Uralensis Root
16%
Helicobacter Pylori
20%
Hemorrhagic Shock
12%
Heparin
16%
Immunity
20%
Immunoglobulin M Antibody
16%
Infectious Mononucleosis
16%
Infliximab
16%
Interstitial Lung Disease
16%
Intestine Injury
16%
Irinotecan
18%
Jejunum
33%
Koji
11%
Laxative
13%
Lung
11%
Lupus Vulgaris
16%
Magnesium
10%
Mental Capacity
11%
Methylation
10%
Mitomycin
16%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
16%
Neoplasm
51%
Nivolumab
16%
Non Erosive Reflux Disease
16%
Non Invasive Procedure
16%
Nonsteroid Antiinflammatory Agent
20%
Omeprazole
14%
Oral Drug Administration
12%
Overall Survival
15%
Pancreas Cancer
28%
Pancreas Carcinoma
16%
Pancreatitis
16%
Polypectomy
16%
Prednisolone
11%
Proctocolectomy
13%
Progression Free Survival
15%
Protein Losing Enteropathy
16%
Proton-Pump Inhibitor
16%
Pulmonary Infiltrate
11%
Pyoderma gangrenosum
11%
Randomized Controlled Trial
33%
Recurrent Disease
10%
Reflux Esophagitis
16%
Retrospective Study
21%
Salivation
14%
Self-Expandable Metallic Stent
16%
Stenosis
21%
Total Stomach Resection
16%
Transitional Cell Carcinoma
16%
Ulcer
40%
Ulcerative Colitis
33%
Vanilloid Receptor 4
16%
Vasodilator Agent
10%
Warfarin
19%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
88%
Acute Pancreatitis
21%
Adalimumab
13%
Adverse Event
20%
Amino Acid
8%
Amoxicillin
16%
Amrubicin
20%
Anemia
9%
Anticoagulant Agent
16%
Antihypertensive
16%
Ascites
5%
Asthma
8%
Autoimmune Disease
7%
Binimetinib
6%
Branched Chain Amino Acid
8%
Capecitabine Plus Oxaliplatin
8%
Carcinogenesis
16%
Chemotherapy
100%
Chemotherapy Induced Nausea and Vomiting
8%
Cisplatin
57%
Citrulline
8%
Citrullinemia Type II
16%
Clinical Trial
27%
Collagen Disease
5%
Colorectal Carcinoma
8%
Combination Therapy
12%
Complement Component C3
5%
Constipation
21%
Crohn's Disease
16%
Cytokine
16%
Diarrhea
39%
Digestive System Cancer
16%
Diseases
8%
Docetaxel
50%
Down Syndrome
16%
Dysphagia
8%
Esophageal Squamous Cell Carcinoma
16%
Esophagus Cancer
10%
Esophagus Tumor
16%
First-Line Chemotherapy
7%
Flapping Tremor
8%
Fluoropyrimidine
36%
Fluorouracil
19%
Gemcitabine
11%
Gimeracil
5%
Helicobacter Pylori
16%
Hepatic Encephalopathy
8%
Human Serum Albumin
5%
Hyperammonemia
8%
Immune Checkpoint Inhibitor
10%
Immunoglobulin A
16%
Inflammatory Bowel Disease
24%
Infliximab
33%
Injury
19%
Irinotecan
26%
Irritable Colon
8%
Jaundice
14%
Kanamycin
8%
Koji
16%
Lactulose
8%
Lafutidine
16%
Laxative
13%
Liver Metastasis
8%
Lupus Vulgaris
16%
Maximum Tolerated Dose
9%
Mercaptopurine
16%
Metabolic Disorder
8%
Metronidazole
16%
Mitogen Activated Protein Kinase Kinase Inhibitor
8%
Mitomycin
16%
Monotherapy
20%
Mouse Model
5%
Nedaplatin
16%
Neuroendocrine Carcinoma
33%
Neutropenia
9%
Normal Human
8%
Oteracil Potassium
5%
Overall Survival
36%
Paclitaxel
33%
Pancreas Cancer
16%
Pancreatitis
19%
Progression Free Survival
34%
Protein Losing Gastroenteropathy
16%
Proton Pump Inhibitor
14%
Purpura
6%
Rabeprazole
16%
Ramucirumab
16%
Remission
5%
Retina Detachment
8%
Rikkunshito
8%
Second-Line Chemotherapy
12%
Small Cell Carcinoma
8%
Stag
16%
Syndrome
8%
Tegafur
5%
Tumor Necrosis Factor Inhibitor
16%
Ulcerative Colitis
16%
Vasculitis
16%
Vasodilator Agent
10%
Vasopressin
8%